Executive Summary
This intelligence stream analyzes 10 DEF 14A filings, revealing a stark bifurcation in the US small-cap and SPAC landscape. A dominant theme is existential distress: 4 of the 10 companies (Veritone, Origin Materials, Klotho Neurosciences, and multiple SPACs) are facing going-concern risks, liquidation, or Nasdaq non-compliance, with a combined materiality score of 8-10/10.
This contrasts sharply with the operational strength of AZZ Inc., which reported record sales and profitability, a 40%+ share price increase, and a 39th consecutive year of profitability. The SPAC sector remains under severe pressure, with Bowen, Mountain Lake, and Pantages all seeking last-minute deadline extensions to avoid liquidation, highlighting a systemic failure to consummate deals. Insider activity is notably absent in most filings, but the unanimous board recommendations for dissolution at Origin Materials and the high insider ownership (70.3%) at Bowen voting for an extension provide critical signals. Period-over-period comparisons from AZZ show strong debt reduction ($385.3M) and shareholder returns ($43M in dividends/buybacks), while the distressed companies show deteriorating equity structures via reverse splits and massive share increases. The most actionable insights revolve around the binary outcomes of SPAC liquidations, the value-destructive nature of reverse splits, and the relative safe-haven of established industrial performers like AZZ.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: DEF 14A
Tracking the trend? Catch up on the prior US Executive Compensation Proxy SEC Filings digest from May 22, 2026.
Investment Signals (10)
- AZZ Inc. ↓ (BULLISH)▲
Record annual sales and profitability, share price up 40%+, 39th consecutive year of profitability, debt reduced by $385.3M, and $43M returned to shareholders via dividends ($23M) and buybacks ($20M). This signals a robust, cash-generating business with strong management execution.
- Origin Materials ↓ (BEARISH)▲
Board unanimously recommends dissolution after a strategic review failed to find a viable alternative. This is a clear signal that management sees zero value creation potential as a going concern, making the stock a likely zero.
- Veritone ↓ (BEARISH)▲
Proposing to increase authorized shares by 50% (from 150M to 225M) and facing a going concern risk related to $1.75% convertible notes due Nov 2026. This massive dilution and debt overhang signals severe financial distress.
- Klotho Neurosciences ↓ (BEARISH)▲
Proposing a reverse stock split (up to 1-for-60) to regain Nasdaq compliance, with the stock having 121M shares outstanding and a history of multiple name changes. This is a classic distressed micro-cap signal with high risk of further value destruction.
-
Insiders (Sponsors, officers, directors) own 70.3% of shares and intend to vote FOR the extension, making approval virtually certain. This high insider alignment reduces the risk of immediate liquidation but doesn't guarantee a successful deal. [NEUTRAL/BULLISH for short-term survival]
- Mountain Lake Acquisition Corp ↓ (BEARISH)▲
The filing highlights a risk of Nasdaq listing failure for the target company (Pubco, symbol 'AVAT') and insufficient cash after redemptions. This suggests the underlying business combination is fragile and may not close.
- Pantages Capital Acquisition Corp (BEARISH)▲
The sponsor may purchase public shares to influence the vote, which could reduce the public float and endanger the listing. This is a desperate measure indicating a weak deal and potential for manipulation.
- Fly-E Group ↓ (BEARISH)▲
Proposing a reverse stock split (1-for-5 to 1-for-100) with only 1.63M shares outstanding. The wide ratio range signals uncertainty about the stock price trajectory and a need to engineer a higher share price.
- Profusa ↓ (BEARISH)▲
Proposing a massive 695,544 share increase to its 2025 Equity Plan (from 100,386 to 795,930), a ~693% increase, alongside a reverse split (up to 1-for-200). This extreme dilution is highly punitive to existing shareholders.
- OSR Holdings ↓ (NEUTRAL)▲
Proposing a name change to 'OSR Health, Inc.' and increasing the Omnibus Incentive Plan by 27% (from 6.3M to 8M shares). Name changes often signal a strategic pivot, but the equity plan increase is dilutive.
Risk Flags (10)
- Veritone/Going Concern↓ [HIGH RISK]▼
The company has identified material weaknesses in internal control and faces a going concern risk related to its ability to repay $1.75% convertible notes due November 2026. This is a high-probability default risk.
- Origin Materials/Liquidation↓ [HIGH RISK]▼
The Board unanimously recommends dissolution, acknowledging that continuing as a going concern is not reasonably likely to create greater value. Shareholders are facing a total loss of equity value.
- Klotho Neurosciences/Nasdaq Delisting↓ [HIGH RISK]▼
The company is proposing a reverse stock split to regain the $1.00 minimum bid price. Failure to do so by March 31, 2027, will result in delisting. The company's history of multiple name changes adds to governance risk.
- Bowen Acquisition Corp/Liquidation↓ [HIGH RISK]▼
If the Extension Proposal is not approved and no business combination is completed by June 14, 2026, the company will redeem public shares and liquidate. This is a binary event with a hard deadline.
- Mountain Lake Acquisition Corp/Deal Failure↓ [HIGH RISK]▼
The proxy statement notes risks of Nasdaq listing failure for the target company (Pubco, 'AVAT'), insufficient cash after redemptions, and the impact of new SEC SPAC rules. These are multiple failure points for the business combination.
- Pantages Capital Acquisition Corp/Public Float Reduction [MEDIUM RISK]▼
The sponsor may purchase public shares to influence the vote, which could reduce the public float and potentially impact the listing of the company's securities. This creates an artificial and potentially misleading voting dynamic.
- Fly-E Group/Reverse Split Risk↓ [MEDIUM RISK]▼
The proposed reverse stock split (1-for-5 to 1-for-100) is a wide range, indicating the stock is trading at very low levels and the company is desperate to maintain its listing. Reverse splits are historically value-destructive.
- Profusa/Extreme Dilution↓ [HIGH RISK]▼
The proposal to increase the equity plan by 693% and authorize a 1-for-200 reverse split signals extreme financial distress and a high likelihood of massive shareholder dilution.
- Veritone/Internal Control Weakness↓ [MEDIUM RISK]▼
The company has identified material weaknesses in internal control over financial reporting. This is a red flag for governance and financial reporting reliability.
- Multiple SPACs/Systemic Risk [HIGH RISK]▼
Three SPACs (Bowen, Mountain Lake, Pantages) are all seeking deadline extensions on the same day (May 26, 2026), indicating a systemic failure in the SPAC market to complete de-SPAC transactions.
Opportunities (8)
- AZZ Inc./Industrial Strength↓ (OPPORTUNITY)◆
With record sales, 39 years of consecutive profitability, a 40%+ stock price increase, and a new facility in Missouri achieving profitability, AZZ is a standout performer. The company's ability to reduce debt by $385.3M while returning capital to shareholders signals a strong, disciplined management team.
-
With insiders owning 70.3% of shares and voting for the extension, the risk of a 'no' vote is minimal. This provides a near-term catalyst for the stock to avoid liquidation, though the long-term deal risk remains. [OPPORTUNITY for short-term traders]
- Origin Materials/Dissolution Value↓ (SPECULATIVE OPPORTUNITY)◆
While the company is liquidating, the Board's ability to determine the timing and method of dissolution could create a residual value opportunity if the company has hidden assets or cash on hand.
-
With the 1.75% convertible notes due Nov 2026 trading at distressed levels and the company seeking to increase authorized shares, there may be an opportunity for distressed debt investors to negotiate a favorable restructuring. [OPPORTUNITY for distressed debt investors]
- Pantages Capital Acquisition Corp/MacMines Deal (SPECULATIVE OPPORTUNITY)◆
The underlying business combination with MacMines Austasia (mining lease in Queensland) could have significant value if the deal closes. The removal of the $5M net tangible assets condition suggests the parties are committed to closing.
- Mountain Lake Acquisition Corp/AVAT Target↓ (SPECULATIVE OPPORTUNITY)◆
The target company (Pubco, symbol 'AVAT') could be a high-growth opportunity if the deal closes and the Nasdaq listing issue is resolved. The risks are high, but the potential reward could be significant.
- Profusa/PanOmics Assay Acquisition↓ (SPECULATIVE OPPORTUNITY)◆
The acquisition of the PanOmics Assay asset from Bio Insights LLC via convertible preferred stock could be a transformative technology acquisition if the assay has commercial potential. The heavy dilution is a major offset.
- OSR Holdings/Name Change Catalyst↓ (OPPORTUNITY)◆
The proposed name change to 'OSR Health, Inc.' could signal a strategic pivot into a higher-growth healthcare segment, potentially attracting new investors and re-rating the stock.
Sector Themes (5)
- SPAC Distress is Systemic◆
Three of the 10 filings (Bowen, Mountain Lake, Pantages) are SPACs seeking last-minute deadline extensions to avoid liquidation. This pattern indicates a systemic failure in the SPAC market to complete de-SPAC transactions, likely due to poor target quality, regulatory headwinds, and a lack of investor appetite. The aggregate materiality of these filings is 8/10, signaling high risk for the sector.
- Reverse Splits as a Distress Signal◆
Four companies (Klotho, Fly-E, Profusa, and Veritone via share increase) are proposing reverse stock splits or massive equity plan increases. This is a classic sign of financial distress and Nasdaq non-compliance, with the average proposed split ratio being extreme (up to 1-for-200). These actions are historically value-destructive for shareholders.
- Going Concern Risks are Concentrated◆
Veritone and Origin Materials are explicitly facing going concern or dissolution risks. This concentration of existential threats in a single day's filings (May 26, 2026) suggests a broader weakness in small-cap companies with weak balance sheets and unprofitable business models.
- Industrial Strength vs. Speculative Weakness◆
AZZ Inc. stands out as a beacon of operational and financial strength, with record profitability, debt reduction, and shareholder returns. This contrasts sharply with the other 9 filings, which are characterized by distress, dilution, or liquidation. This suggests a 'flight to quality' within the small-cap space.
- Insider Alignment is a Key Signal◆
In the SPAC filings, high insider ownership (Bowen at 70.3%) is used to ensure approval of extension proposals. This alignment can be a positive signal for short-term survival but does not guarantee long-term value creation. The absence of insider buying in distressed companies (Veritone, Origin) is a negative signal.
Watch List (8)
-
The Extraordinary General Meeting to vote on the extension is critical. Approval is virtually certain due to insider ownership, but the redemption rate will signal investor confidence. Watch for the redemption amount post-vote. Date: June 14, 2026 deadline.
-
The vote on the Plan of Complete Liquidation and Dissolution on July 1, 2026. Watch for any last-minute alternative transactions or shareholder activism to block the dissolution. Date: July 1, 2026.
-
The $1.75% convertible senior notes due November 2026 are a ticking time bomb. Watch for any refinancing, restructuring, or equity issuance to address this debt. Date: November 2026.
-
The business combination with AVAT (Pubco) is at risk due to Nasdaq listing issues and cash concerns. Watch for any updates on the target's listing status and the final redemption rate. Date: TBD, but extension is being sought.
- Pantages Capital Acquisition Corp/Sponsor Share Purchases👁
Watch for any filings disclosing sponsor purchases of public shares, which would signal desperation and potential manipulation. The deadline for the business combination is June 6, 2026.
-
The reverse stock split must be completed by March 31, 2027. Watch for the exact split ratio and any subsequent price action to see if the stock can maintain the $1.00 bid price. Date: March 31, 2027.
-
With record sales and a new facility achieving profitability, watch for the next earnings call for guidance on continued margin expansion and debt reduction. The annual meeting is July 7, 2026.
-
The vote on the massive equity plan increase and reverse split on June 23, 2026. Watch for the approval rate and any shareholder dissent. Date: June 23, 2026.
Filing Analyses
(10)
26-05-2026
Veritone, Inc. filed a definitive proxy statement (DEF 14A) for its 2026 Annual Meeting of Stockholders to be held virtually on July 7, 2026. The meeting will include votes on electing two Class III directors, ratifying CBIZ CPAs P.C. as auditor, an advisory vote on executive compensation, and several capital structure proposals including increasing authorized common shares from 150 million to 225 million, amending the 2023 Equity Incentive Plan, and approving CEO Strategic Awards. The filing also highlights significant forward-looking risks, including the company's ability to continue as a going concern and repay its 1.75% convertible senior notes due November 2026.
- · The company has identified material weaknesses in internal control over financial reporting and is pursuing remediation.
- · Veritone faces a going concern risk related to its ability to repay $1.75% convertible senior notes due November 2026.
- · The proxy statement includes a proposal to increase authorized common shares from 150,000,000 to 225,000,000.
- · Stockholders of record as of May 19, 2026 are entitled to vote at the annual meeting.
- · The annual meeting will be held virtually on July 7, 2026 at 10:30 a.m. Pacific Time.
26-05-2026
Bowen Acquisition Corp (BOWN) is seeking shareholder approval at an Extraordinary General Meeting to extend the deadline for its initial business combination with Qianzhi from June 14, 2026 to an Extended Date. The Sponsors, officers and directors, who beneficially own 2,066,782 ordinary shares (70.3% of outstanding shares), intend to vote in favor of the Extension Proposal, making approval virtually certain. However, if the proposal is not approved and no business combination is completed by June 14, 2026, the company will redeem public shares and liquidate, with holders of Founder Shares and Private Shares receiving nothing from the Trust Account.
- · The Extension Proposal requires approval by at least two-thirds of the votes cast at the Extraordinary General Meeting.
- · The Adjournment Proposal requires a simple majority of votes cast and will not be presented if the Extension Proposal is approved.
- · If the Extension Proposal is not approved and no business combination is completed by June 14, 2026, the company will redeem public shares and liquidate within ten business days.
- · Shareholders who did not redeem in connection with the January 2025 vote for the Qianzhi business combination will not have redemption rights for this proposal.
- · No appraisal or dissenters' rights exist under Cayman Islands law for the Extension Proposal.
- · The record date for voting is May 15, 2026.
26-05-2026
Greenland Mines Ltd (formerly Klotho Neurosciences, Inc.) filed a definitive proxy statement (DEF 14A) for a special meeting of stockholders to be held on June 18, 2026. The primary proposal seeks approval for one or more reverse stock splits with exchange ratios between 1-for-2 and 1-for-50 (aggregate not exceeding 1-for-60) to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company has 121,238,660 shares of common stock outstanding as of the April 23, 2026 record date, and a quorum requires at least 33⅓% of outstanding shares.
- · The special meeting will be held virtually via Zoom on June 18, 2026 at 1:00 p.m. Eastern Time.
- · The reverse stock split must be completed by March 31, 2027, with the aggregate exchange ratio not exceeding 1-for-60.
- · The company has changed its name multiple times: from Redwoods Acquisition Corp. (Jan 2022) to ANEW Medical, Inc. (Jun 2024) to Klotho Neurosciences, Inc. (Oct 2024) to Greenland Mines Ltd.
- · Proxy materials will be mailed to stockholders on or about May 28, 2026.
- · The board of directors has no interest in the proposals other than their share ownership.
26-05-2026
Origin Materials, Inc. is seeking stockholder approval to dissolve and liquidate the company under a Plan of Complete Liquidation and Dissolution, following a lengthy strategic review that failed to identify a viable alternative transaction. The Board of Directors unanimously recommends approval, citing low probability of a superior strategic alternative and the ability to distribute residual value to stockholders more quickly through dissolution. However, the company acknowledges that continuing as a going concern is not reasonably likely to create greater value, and the dissolution process will incur material costs and result in no ongoing business operations.
- · The Special Meeting will be held virtually on July 1, 2026, at 8:30 a.m. Pacific Time.
- · Record date for voting is May 20, 2026.
- · The Board of Directors has sole discretion to determine if and when to proceed with dissolution after stockholder approval.
- · A contingency reserve of cash and/or property will be set aside to satisfy claims and contingent obligations.
- · The dissolved corporation will continue to exist for three years after dissolution for winding up purposes.
- · The Board may abandon or delay dissolution prior to filing the Certificate of Dissolution if circumstances change.
- · Stockholders will vote on two proposals: approval of the Plan of Dissolution and an adjournment proposal.
- · The company's management and Board canvassed the market for potential transactions but found none providing superior value.
26-05-2026
OSR Holdings, Inc. filed a definitive proxy statement (DEF 14A) for its annual meeting to be held on June 18, 2026. The meeting will include votes on five proposals: election of seven directors, ratification of independent auditor, advisory approval of executive compensation, amendment to the 2025 Omnibus Incentive Plan to increase shares from 6,300,000 to 8,000,000, and a corporate name change to OSR Health, Inc. The Board recommends a vote 'FOR' all proposals.
- · The annual meeting is required by Nasdaq Listing Rule 5620(a) to be held within 12 months after fiscal year ended December 31, 2025.
- · Record date for voting is May 6, 2026.
- · Proxy materials are available at https://www.cstproxy.com/osr-holdings/2026.
- · The company's principal executive offices are at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004.
26-05-2026
Fly-E Group, Inc. filed a definitive proxy statement (DEF 14A) for its 2025 Annual General Meeting to be held on June 17, 2026. The meeting will include proposals to elect four directors, ratify Fortune CPA as independent auditor, approve a reverse stock split (1-for-5 to 1-for-100), and authorize adjournments if needed. As of the May 5, 2026 record date, 1,632,386 shares of common stock were outstanding and entitled to vote.
- · The reverse stock split ratio range is 1-for-5 to 1-for-100, with the exact ratio determined by the board within one year after the meeting.
- · The record date for voting is May 5, 2026.
- · Proxy materials will be mailed on or about May 26, 2026.
- · Stockholders can vote by mail, email, phone, internet, or in person at the meeting.
26-05-2026
Mountain Lake Acquisition Corp. filed a DEF 14A proxy statement on May 26, 2026, seeking shareholder approval for an extension of the deadline to complete an initial business combination (the 'Articles Extension Proposal'). The filing highlights significant risks, including the possibility that the company may not complete a business combination by the extended deadline, which would lead to liquidation and dissolution, with public shares redeemed at the trust account per-share price and rights expiring worthless. Additionally, the proxy statement notes that the sponsor, certain directors, and officers have interests that may conflict with other shareholders, and that the company faces challenges such as potential Nasdaq listing failure for the target company (Pubco, proposed symbol 'AVAT'), insufficient cash after redemptions, and the impact of new SEC SPAC rules.
- · The proxy statement includes a cautionary note regarding forward-looking statements and risk factors.
- · The company is required to offer shareholders redemption rights in connection with the Articles Extension Proposal and again in connection with any shareholder vote to approve an initial business combination.
- · If the business combination is not completed, the company will cease operations, redeem public shares (at a per-share price equal to the trust account balance divided by outstanding public shares), and dissolve, subject to Cayman Islands law and creditor claims.
- · The company has applied to list Pubco's securities on Nasdaq under the symbol 'AVAT', but no assurance is given that the listing will be approved.
- · The filing references the SEC's 2024 SPAC Rules, which became effective July 1, 2024, and may materially affect the company's ability to complete its initial business combination.
- · The Inflation Reduction Act of 2022 imposes a 1% excise tax on certain stock repurchases by publicly traded domestic corporations, which could apply to redemptions in connection with the business combination.
- · The proxy statement notes that the sponsor, certain directors, and officers have interests that may conflict with other shareholders, including that founder shares and private rights would be worthless if the extension is not approved and no business combination is completed.
26-05-2026
Profusa, Inc. has filed a Definitive Proxy Statement (DEF 14A) for its virtual 2026 Annual Meeting of Stockholders scheduled for June 23, 2026. The Board recommends voting FOR six proposals: electing Lauren Chung as a Class I director, authorizing a reverse stock split (1-for-5 to 1-for-200), approving the issuance of convertible preferred stock to Bio Insights LLC for the PanOmics Assay asset acquisition, approving the potential issuance of common stock upon conversion of a promissory note to NorthView Sponsor I LLC, amending the 2025 Equity Plan to increase authorized shares from 100,386 to 795,930 (a 695,544 share increase), and authorizing adjournment if necessary. The proxy statement includes detailed compensation and governance disclosures.
- · The annual meeting will be held virtually on June 23, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/PFSA2026.
- · Stockholders of record as of May 12, 2026 are entitled to vote.
- · A failure to vote or abstention will have the same effect as a vote AGAINST Proposals 2 through 6.
- · The reverse stock split may be effected at a ratio within a range of 1-for-5 to 1-for-200, at the Board's discretion, at any time on or before June 23, 2028.
- · The Asset Purchase Agreement with Bio Insights LLC for the PanOmics Assay was dated April 21, 2026.
- · The Note Modification and Conversion Agreement with NorthView Sponsor I LLC was dated April 24, 2026, and amended on April 29, 2026.
- · The company's principal executive offices are located at 626 Bancroft Way, Suite A, Berkeley, CA 94710.
26-05-2026
AZZ Inc. filed its definitive proxy statement (DEF 14A) for the 2026 Annual Meeting of Shareholders, highlighting record annual sales and profitability, a 39th consecutive year of profitability from continuing operations, and a share price increase of over 40%. However, softer conditions in certain Precoat Metals markets partially offset strong Metal Coatings segment results, and the company reduced debt by $385.3 million while returning $23.0 million in dividends and $20.0 million in share repurchases.
- · The new aluminum coil coating facility in Washington, Missouri achieved profitability during Q4 of fiscal year 2026.
- · The company eliminated 6,691 sets of proxy materials through E-Delivery, saving 7,318 pounds of paper.
- · Record date for voting is May 8, 2026; annual meeting is July 7, 2026 at 10:00 a.m. Central Time.
- · Two new independent directors were appointed effective April 8, 2026, adding cyber and AI expertise.
- · The Board recommends a vote FOR all eight director nominees, FOR advisory approval of executive compensation, and FOR ratification of Grant Thornton LLP as auditor.
26-05-2026
Pantages Capital Acquisition Corp filed a DEF 14A proxy statement on May 26, 2026, seeking shareholder approval for an extension of the deadline to complete a business combination from June 6, 2026, and related trust agreement amendments. The company has entered into a Business Combination Agreement with MacMines Austasia Pty Ltd and related entities for a merger that would result in Pubco becoming the parent company, with MacMines contributing a mining lease application in Queensland, Australia. The board unanimously recommends voting 'FOR' all proposals, but the filing also discloses that the sponsor may purchase public shares to influence the vote, which could reduce the public float and potentially impact the listing of the company's securities.
- · The deadline to consummate a business combination is June 6, 2026; if not approved, the company will redeem public shares and liquidate.
- · Amendment No. 1 to the Merger Agreement (April 14, 2026) removed the condition that the company have net tangible assets of at least $5,000,001 after redemptions.
- · The sponsor may purchase public shares outside the redemption offer, but such shares cannot be voted for the Extension Proposal, potentially reducing the public float and endangering the listing.
- · The Extraordinary General Meeting will be held at 44 Montgomery St, San Francisco, CA 94104 and virtually via teleconference (registration required).
- · Record date for voting is May 20, 2026.
- · Approval of the Extension Proposal requires a special resolution (at least two-thirds of votes cast).
- · Approval of the Adjournment Proposal requires an ordinary resolution (simple majority).
Get daily alerts with 10 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 10 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US Executive Compensation Proxy SEC Filings
🇺🇸 More from United States
View all →May 28, 2026
US Pre-Market SEC Filings Roundup — May 28, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals